Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia
Open Access
- 1 May 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (9), 3442-3446
- https://doi.org/10.1182/blood-2005-02-0833
Abstract
Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed.This publication has 14 references indexed in Scilit:
- Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patientsLeukemia, 2005
- Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s MacroglobulinemiaJournal of Clinical Oncology, 2005
- Extended rituximab therapy in Waldenström's macroglobulinemiaAnnals of Oncology, 2005
- Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)Leukemia & Lymphoma, 2004
- Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cellsBlood, 2004
- Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and CyclophosphamideLeukemia & Lymphoma, 2003